SOURCE: Stock Market Alerts
|
October 17, 2007 09:10 ET
Breaking Stock Alert for Wednesday: POSC! October 17, 2007
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Stock Market Alerts.
MIAMI, FL--(Marketwire - October 17, 2007) - Stock Market Alerts' performance stock list
includes: Positron Corporation (OTCBB: POSC), General Electric Company
(NYSE: GE), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ).
Targeting the multi-billion dollar medical imaging industry, Positron
Corporation (OTCBB: POSC) should have investors monitoring the stock
closely! Yesterday after the markets closed, the company, which designs,
manufactures, markets and supports advanced cardiac molecular imaging
devices utilizing single photon emission computed tomography (SPECT) and
positron emission tomography (PET), issued a press release announcing that
it displayed their PULSE CDC™ SPECT imaging system, as well as
introduced their new dedicated Cardiac PET system that is expected to
receive 510k FDA approval in spring 2008, at the Annual meeting of The
American Society of Nuclear Cardiology.
This is good news for POSC, as the meeting attendees consisted of more than
1,500 nuclear cardiologists, practice administrators and technologists with
the majority operating myocardial perfusion imaging with private cardiology
practices. Market research from the ASNC meeting suggested that the
cardiologist market would readily move to compliment their molecular
imaging offering by adding Positron's cost effective Attrius system
especially due to the proposed cardiac PET reimbursement increase (Jan 1,
2008).
Continue to watch this company! According to the press release, Positron is
expecting significant demand for their product since they will be the only
vendor offering an all new PET only molecular imaging system for less than
$600,000 with the primary focus on cardiology. Positron intends to be the
first company to offer absolute coronary flow reserve calculations
developed by K. Lance Gould, M.D. Dr. Gould is considered the founder of
Cardiac PET combined with the discovery of flow reserve in human studies.
Positron Corporation's President, Joseph Oliverio stated, "The American
Society of Nuclear Cardiology meeting confirmed our internal market
research. We strongly believe that we are in a great position to be the
leader in the rapidly expanding market of Cardiac PET. We will be the only
company that is focused on bringing to market an affordable dedicated
cardiac PET scanner with superior technology and disease focused software.
We anticipate receiving our 510k FDA approval in spring of 2008."
The company's stock closed at Six cents a share
Positron Corporation designs, manufactures, markets and supports advanced
cardiac molecular imaging devices utilizing single photon emission computed
tomography (SPECT) and positron emission tomography (PET). The company's
molecular imaging systems incorporate patented and proprietary software and
hardware technology for the diagnosis and treatment of patients with heart
disease. Positron Corporation offers unique combination of low cost
technology and disease specific software solutions differentiating
themselves from all other medical device manufacturers.
Other Stocks of interest yesterday were:
General Electric Company (NYSE: GE) down 0.1% on 35.2 million shares
traded.
GE, a diversified technology, media and financial services company focused
on solving some of the world's toughest problems. With products and
services ranging from aircraft engines, power generation, water processing
and security technology to medical imaging, business and consumer
financing, media content and advanced materials, GE serves customers in
more than 100 countries and employs more than 300,000 people worldwide.
Pfizer Inc. (NYSE: PFE) down 1.4% on 44.5 million shares traded.
Pfizer is committed to helping people improve their health by discovering
and developing medicines, as well as informing consumers and health care
providers about our medicines and the medical conditions they treat.
Through multiple initiatives, Pfizer aims to enhance access to treatments
and educate, empower and motivate consumers to take the necessary steps to
lead longer, healthier, happier lives.
Johnson & Johnson (NYSE: JNJ) down 0.8% on 14.3 million shares traded.
Johnson & Johnson is a manufacturer of health care products.
The advertisement is provided by Wall Street Enews, a division of Stock
Market Alerts LLC, an electronic broadcaster and publisher of this release,
and hereafter referred to as "the company." The company received
compensation for services performed for Positron Corporation (OTCBB: POSC).
The compensation was fourteen thousand dollars, from third party, GDB Media
Inc., who may hold a significant position in the stock. Because the company
received compensation for its services, there is an inherent conflict of
interest in the company statements and opinions and such statements and
opinions cannot be considered independent.
The information contained in this press release is for informational
purposes only, and not to be construed as an offer to sell or solicitation
of an offer to buy any security. The company makes no representation or
warranty relating to the validity of the facts presented nor does the
company represent or warrant that all material facts necessary to make an
investment decision are presented above. Stock Market Alerts LLC is an
advertising company and therefore, this release should be viewed for
informational purposes only.
The company relies exclusively on information gathered on the public
company, such as public filings, press releases and its web sites.
Investors should use the advertising information contained in this release
as a starting point for conducting additional research on the public
company in order to allow the investor to form his or her own opinion
regarding the public company. Factual statements contained in this
publication are made as of the date stated and they are subject to change
without notice. The company is not a registered investment adviser, broker
or a dealer.
Investing in the public company that this release is providing service for
should be reviewed as speculative and a high-risk and may result in the
loss of some or all of any investment.
This release may contain statements that constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933,
as amended, and Section 21E the Securities Exchange Act of 1934, as
amended. The words "may," "would," "will," "expect," "estimate,"
"anticipate," "believe," "intend," and similar expressions and variations
thereof are intended to identify forward-looking statements.